Loading...
Docoh

Freeline Therapeutics (FRLN)

82 filings

Newest first
Filter options loading...
Top filers
Top filing types
Recent filing years
6-K
FRLN Freeline Therapeutics Holdings plc
23 May 22
Current report (foreign)
4:06pm
6-K
2022 Q1
FRLN Freeline Therapeutics Holdings plc
10 May 22
Freeline Reports First Quarter 2022 Financial Results and Business Highlights
4:02pm
6-K
FRLN Freeline Therapeutics Holdings plc
19 Apr 22
Freeline Appoints Paul Schneider as Chief Financial Officer
8:00am
424B5
FRLN Freeline Therapeutics Holdings plc
7 Apr 22
Prospectus supplement for primary offering
5:14pm
6-K
FRLN Freeline Therapeutics Holdings plc
31 Mar 22
Freeline Reports Full Year 2021 Financial Results and Business Highlights
4:10pm
20-F
2021 FY
FRLN Freeline Therapeutics Holdings plc
31 Mar 22
Annual report (foreign)
4:02pm
SC 13D
FRLN Freeline Therapeutics Holdings plc
25 Mar 22
Freeline Therapeutics / Syncona Portfolio ownership change
4:07pm
6-K
FRLN Freeline Therapeutics Holdings plc
24 Mar 22
Freeline Announces Updated Development Plan and Timelines for FLT190 for People with Fabry Disease
7:00am
6-K
FRLN Freeline Therapeutics Holdings plc
23 Mar 22
Current report (foreign)
4:05pm
424B5
FRLN Freeline Therapeutics Holdings plc
22 Mar 22
Prospectus supplement for primary offering
4:17pm
SC 13G
FRLN Freeline Therapeutics Holdings plc
21 Mar 22
Freeline Therapeutics / Tetragon Financial Management ownership change
11:10am
6-K
FRLN Freeline Therapeutics Holdings plc
15 Mar 22
Current report (foreign)
4:06pm
424B5
FRLN Freeline Therapeutics Holdings plc
11 Mar 22
Prospectus supplement for primary offering
7:59am
6-K
FRLN Freeline Therapeutics Holdings plc
9 Mar 22
Freeline Announces First Patient Dosed in the Phase 1/2 B-LIEVE Dose-Confirmation Trial in Hemophilia B
7:00am
SC 13G/A
FRLN Freeline Therapeutics Holdings plc
14 Feb 22
Freeline Therapeutics / EVENTIDE ASSET MANAGEMENT ownership change
11:47am
SC 13G
FRLN Freeline Therapeutics Holdings plc
11 Feb 22
Freeline Therapeutics / CHI Advisors ownership change
1:00pm
SC 13G/A
FRLN Freeline Therapeutics Holdings plc
11 Feb 22
Freeline Therapeutics / Syncona Portfolio ownership change
12:20pm
6-K
FRLN Freeline Therapeutics Holdings plc
8 Feb 22
Freeline Presents on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposiumTM
7:00am
SC 13G/A
FRLN Freeline Therapeutics Holdings plc
4 Feb 22
Freeline Therapeutics / WELLINGTON MANAGEMENT ownership change
9:06am
6-K
FRLN Freeline Therapeutics Holdings plc
3 Feb 22
Freeline Appoints Henning R. Stennicke, PhD, As Chief Scientific Officer to Lead Research and Discovery
9:01am